Neuron23

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Neuron23 sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 1 currently recruiting early-phase tilt upper half by trial count

Neuron23: 2 sponsored US clinical trials, 1 recruiting.

Neuron23 sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Early Parkinson Disease (Early PD), with 1 trials.

Mid-pack sponsor footprint

Neuron23 is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the Neuron23 pipeline

1 recruiting of 2 indexed (50% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Early Parkinson Disease (Early PD) (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Neuron23: open-pipeline peers nationwide

Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Neuron23 sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60% Total trials Recruiting share Neuron231200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health3ive Labs60 Degrees Pharmaceuticals7 Hills PharmaAbcentra
Neuron23 sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Neuron23 sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Neuron23 page

2 registered trials is a research-attention snapshot, not an endorsement of Neuron23 or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Neuron23 pipeline card: 2 registered trials from official public datasets.Report a data error.